These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22948869)

  • 41. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
    Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
    Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.
    Louie A; Kaw P; Banerjee P; Liu W; Chen G; Miller MH
    Antimicrob Agents Chemother; 2001 Feb; 45(2):485-94. PubMed ID: 11158745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The synergistic antifungal effects of gypenosides combined with fluconazole against resistant Candida albicans via inhibiting the drug efflux and biofilm formation.
    Liu Y; Ren H; Wang D; Zhang M; Sun S; Zhao Y
    Biomed Pharmacother; 2020 Oct; 130():110580. PubMed ID: 32745913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence.
    Zhang M; Yan H; Lu M; Wang D; Sun S
    Int J Antimicrob Agents; 2020 Jan; 55(1):105804. PubMed ID: 31605727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans.
    de Sá NP; de Paula LFJ; Lopes LFF; Cruz LIB; Matos TTS; Lino CI; de Oliveira RB; de Souza-Fagundes EM; Fuchs BB; Mylonakis E; Johann S
    J Glob Antimicrob Resist; 2018 Sep; 14():287-293. PubMed ID: 29715565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection.
    Lupetti A; Brouwer CP; Bogaards SJ; Welling MM; de Heer E; Campa M; van Dissel JT; Friesen RH; Nibbering PH
    J Infect Dis; 2007 Nov; 196(9):1416-24. PubMed ID: 17922408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis.
    De Bernardis F; Arancia S; Tringali G; Greco MC; Ragazzoni E; Calugi C; Trabocchi A; Sandini S; Graziani S; Cauda R; Cassone A; Guarna A; Navarra P
    J Pharm Pharmacol; 2014 Aug; 66(8):1094-101. PubMed ID: 24628362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergy of fluconazole with macrophages for antifungal activity against Candida albicans.
    Garcha UK; Brummer E; Stevens DA
    Mycopathologia; 1995-1996; 132(3):123-8. PubMed ID: 8684425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections.
    Niwano Y; Kuzuhara N; Goto Y; Munechika Y; Kodama H; Kanai K; Yoshida M; Miyazaki T; Yamaguchi H
    Int J Antimicrob Agents; 1999 Aug; 12(3):221-8. PubMed ID: 10461840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo.
    Hector RF; Schaller K
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1284-9. PubMed ID: 1416829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors.
    Lacassin F; Damond F; Chochillon C; Longuet P; Lebras J; Vilde JL; Leport C
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1961-3. PubMed ID: 8843316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation between in vitro and in vivo activity of antifungal agents against Candida species.
    Anaissie EJ; Karyotakis NC; Hachem R; Dignani MC; Rex JH; Paetznick V
    J Infect Dis; 1994 Aug; 170(2):384-9. PubMed ID: 8035024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic evaluation of fluconazole in critically ill patients.
    Sinnollareddy M; Peake SL; Roberts MS; Playford EG; Lipman J; Roberts JA
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1431-40. PubMed ID: 21883033
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ambroxol Hydrochloride Combined with Fluconazole Reverses the Resistance of
    Li X; Zhao Y; Huang X; Yu C; Yang Y; Sun S
    Front Cell Infect Microbiol; 2017; 7():124. PubMed ID: 28439502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neonatal coinfection model of coagulase-negative Staphylococcus (Staphylococcus epidermidis) and Candida albicans: fluconazole prophylaxis enhances survival and growth.
    Venkatesh MP; Pham D; Fein M; Kong L; Weisman LE
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1240-5. PubMed ID: 17261622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tinospora cordifolia Aqueous Extract Alleviates Cyclophosphamide- Induced Immune Suppression, Toxicity and Systemic Candidiasis in Immunosuppressed Mice: In vivo Study in Comparison to Antifungal Drug Fluconazole.
    Alrumaihi F; Allemailem KS; Almatroudi A; Alsahli MA; Khan A; Khan MA
    Curr Pharm Biotechnol; 2019; 20(12):1055-1063. PubMed ID: 31333126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy.
    Onyewu C; Afshari NA; Heitman J
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3963-5. PubMed ID: 16923949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
    Hata K; Kimura J; Miki H; Toyosawa T; Nakamura T; Katsu K
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2237-42. PubMed ID: 8891121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis.
    Jafari HS; Sáez-Llorens X; Severien C; Parras F; Friedland I; Rinderknecht S; Ehrett S; Olsen KD; Abramowsky C; McCracken GH
    Antimicrob Agents Chemother; 1994 Jan; 38(1):83-9. PubMed ID: 7511361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [In vivo and in vitro antifungal activity of fluconazole].
    Kawasaki K; Matsumura Y; Ogawa M; Tsuji A; Matsunaga T; Goto S
    Jpn J Antibiot; 1991 May; 44(5):552-61. PubMed ID: 1880935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.